drugset / Trial / NCT02395705
Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
Phase 3
Completed
528 enrolled
Henan Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collabHunan Province Tumor Hospital · collabPeking University Cancer Hospital & Institute · collabSun Yat-sen University · collabTianjin Medical University Cancer Institute and Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The effect of neo-adjuvant chemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains the most controversial part of neo-adjuvant therapy for esophageal carcinomas. One of our objectives is to evaluate whether the neo-adjuvant therapy with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients.
Timeline
- Start
- 2015-06
- Primary completion
- 2022-10
- Completion
- 2022-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 87.5 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |